Women with pathogenic germline MMR gene mutation have 43-48% lifetime risk of developing CRC; the risk is 40%–62% for EC, 2%–13% for gastric cancer (GC), and 6%–14% for ovarian cancer (OC), while the risk of developing other LS-AC also increases greatly. Here, MRC1 is linked to gastric cancer.